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Ovine GM1-gangliosidosis is an autosomal recessive lysosomal storage disorder. 
Affected lambs are born relatively normal, however at approximately four months of age they 
begin exhibiting severe neurological symptoms.  Pathology progresses rapidly in affected lambs 
ultimately resulting in death by five to six months of age.  In humans and other species, 
mutations in the β-galactosidase (GLB1) gene are responsible for similar disease phenotypes.  
The production of non-functional β-galactosidase results in a buildup of GM1 gangliosides and 
other terminally linked galactose-containing molecules in the brain and visceral tissues.  Using 
the Illumina® OvineSNP50 BeadChip platform, seven affected and ten unaffected animals were 
genotyped and a genome wide association analysis was performed using PLINK.  A significant 
association was detected for multiple SNPs on OAR19; further investigation showed this area 
was orthologous to HSA3 containing GLB1.  Sequence analysis revealed a G to T nucleotide 
transversion in exon six of ovine GLB1 resulting in a nonsynonymous cysteine to phenylalanine 
(Cys229Phe) amino acid substitution.  A PCR-RFLP assay using AciI restriction enzyme was 
designed for genotyping lambs.  To date, 1664 animals have been genotyped using the DNA-
based diagnostic and all affected lambs were homozygous for this mutation.  Conversely, 
individuals with normal phenotypes were either heterozygous or homozygous for the 
alternative allele.  Affected lambs will be used as an animal model to further explore the 
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Chapter 1:  Literature Review 
Animal models of human diseases can serve a valuable purpose by providing 
opportunities for improved treatments and therapies.  Laboratory animals like mice and rats 
are often used due to their relative ease of care and lower economic costs as compared to 
larger animals.  However, large animals like sheep, pigs, and larger breed dogs have an anatomy 
and life span more similar to humans than do rodents.  Additionally, the relative size of the 
body and organs also offers an advantage in that translation of results to human physiological 
scale is less of an issue.  Due to these similarities, the symptoms of larger species are also 
typically more representative of those seen in humans [1].  Sheep and other non-laboratory 
animals have been used as models for diseases such as retinal degeneration [2], cardiovascular 
disease [3], congestive heart failure [3-5], cardiomyopathy [6], muscular dystrophy [7], 
Parkinson’s disease [8], and hemophilia [1]. 
1.1 Lysosomal storage disorders 
Lysosomal storage disorders have been observed in many species and are highly 
variable in severity.  They were first discussed by Hers in 1965 [9] whose publication describing 
such a disease led to the classification of many others [10].  A lysosomal storage disorder 
usually results from a deficiency of an enzyme responsible for partial or complete breakdown of 
a molecule within the lysosome.  The accumulation of one or more of these molecules can 
cause a multitude of symptoms that are often incompatible with life.  In most types of these 
disorders, the deficiency is a result of a mutation in the structural gene encoding the respective 
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lysosomal enzyme, where mutated alleles often fail to produce mature functional proteins [10, 
11]. 
In a review of lysosomal storage disorders, Vellodi points out that the high complexity of 
lysosomal enzymes makes for an increased chance of dysfunction [12].  Since Hers first 
published work discovering a storage disorder [13] there have been over 40 other diseases 
characterized [12].  Patel and Pentchev reviewed the major categories of storage issues that 
can be seen in animal models [11].  Sphingolipidoses are the category of disorders that include 
the gangliosidoses.  These disorders are the result of a malfunctioning lysosomal degradation 
process of sphingolipids, molecules found in membranes.  Glycogenoses are disorders in 
metabolism of glycogen; worth mentioning, Pompe’s disease, a glycogen storage disease, was 
the first described lysosomal storage disorder [13].  Glycoproteinoses include all disorders with 
improper degradation of glycoproteins and also include the mannosidoses.  The 
mucopolysaccharidoses are errors in glycosaminoglycans metabolism.  For several diseases, 
there can be an overlap in pathology between glycoproteinoses and mucopolysaccharidoses 
with the former appearing as mild cases of the latter. 
1.1.1 GM1 Gangliosidosis 
GM1 gangliosidosis is a lysosomal storage disorder found in humans [14], cattle [15-17], 
cats [18-20], dogs [21, 22] and sheep [23].  There have also been cases documented in emus 
[24], and a mouse model has been generated [25].  These species all have similar symptoms 
with the primary lesion being a gross deficiency of β-galactosidase.  This results in a subsequent 
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buildup of GM1 gangliosides.  The accumulation leads to severe neurological symptoms and the 
eventual death of the individual.   
There are three types of human GM1 gangliosidosis that vary by the age of onset.  Type I 
(infantile) earns is distinction because onset begins between birth and approximately 6 months 
of age, and progression is rapid.  Death of the affected individual occurs by 2 years of age.  Type 
II (juvenile) progresses slower, and symptoms develop between 7 months and 3 years of age.  
Type III (adult) has a late onset of between 3 and 30 years [26]. GM1 gangliosidosis has been 
documented in animal species as well, with most being similar to the Type II form of the disease 
[16, 22, 27, 28] and one sheep phenotype that is more representative of the more severe Type I 
pathology [29]. 
GM1 gangliosidosis is often the result of autosomal recessive mutations.  Indeed, many 
times, the disease is first identified in offspring that are the result of consanguineous matings.  
As an example, cats determined to have GM1 gangliosidosis had a history of inbreeding prior to 
observation of the neurological dysfunction [30].  In cattle, affected calves were observed after 
a second breeding season with evidence of significant inbreeding [15, 17].  
GM1 gangliosidosis has been observed in cattle since 1971 [15-17].  Signs of the disease 
can be observed within the first month of life but affected calves are not in grave condition 
until 6 to 9 months of age.  The calves are not lively, exhibit ataxia, and fail to gain weight 
resulting in poor body condition.  Upon necropsy, a ballooning of the neurons is found.  Also, 
there is a bulge in cortical grey matter, but all other organs appear to be normal.  There is an 
accumulation of the GM1 ganglioside thus supporting a diagnosis of GM1 gangliosidosis.  
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Because there are no skeletal deformities or visceral changes, it is suggested that this disease is 
most similar to the Type II form of the human disease [16]. 
Instances of GM1-gangliosidosis have also been observed in multiple breeds of cats, 
including Siamese and domestic shorthaired.  When compared to normal cats, the ganglioside 
content in the brain is drastically increased in diseased cats [19, 20, 30, 31].  There is also  a 
recognizable increase in ganglioside concentration in the spleen and liver [30].  β-galactosidase 
activity levels in the brain, liver, and spleen are less than 10% of control cats [19]. 
Alroy, et al., examined two models of GM1 gangliosidosis in three affected puppies with 
lysosomal β-galactosidase activity less than 10% of control levels [21].  The affected puppies 
also had HPLC patterns that were consistent with GM1 gangliosidosis.  Tissues throughout the 
body of affected puppies contained oligosaccharides consistent with a deficiency of β-
galactosidase.  The two different breeds examined, English Springer Spaniel and Portuguese 
Water Dog, showed similar symptoms indicating that the abnormalities paralleled deficiency of 
β-galactosidase causing an increase in storage of GM1 gangliosides and oligosaccharides.  There 
were phenotypic variations in galactose containing storage products in the liver and kidney 
between the two models.  These were likely due to differences in the underlying mutation 
between the breeds.    
1.1.2 Other Sphingolipidoises 
 GM2 gangliosidosis is a build-up of gangliosides, but the excess storage product is a 
different type of ganglioside from the GM1 gangliosidses described previously.  Warren Tay, an 
ophthalmologist, first observed the disease in 1881 [32].  Neurologist Barnard Sachs further 
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examined the diseased patient and noticed a distended cytoplasm in neurons; the disease later 
became known as Tay-Sachs disease [33].  In 1962, Lars Svennerholm demonstrated that the 
underlying cause was a buildup of GM2 gangliosides [34].  Since that time, two other variants of 
GM2 gangliodsidosis have been described in addition to Tay-Sachs disease [35].  Sandhoff 
disease and the AB-variant of GM2 gangliosidosis were identified as deficiencies of other 
enzymes leading to similar symptoms (i.e., a buildup of GM2 gangliosides). 
 GM2 gangliosidosis is caused by a deficiency one or more of the alpha- and beta- 
subunits of hexosaminidase, HEXA and HEXB respectively, and a GM2 activator, GM2A [10, 35].  
Mutations to HEXA cause the Tay-Sachs form of GM2 gangliosidosis while alterations of HEXB 
lead to Sandhoff disease.  Alterations of GM2A cause a deficiency of the GM2 activator and 
what is referred to as the AB Variant of the disease [35]. 
 Other forms of sphingolipidoses include Gaucher’s disease, Type II, Niemann-Pick 
disease, Type A, and Krabbe’s disease.  Gaucher’s disease, Type II is a buildup of 
glucosylceramide and glucosylpsychosine due to a lack of β-glucocerebrosidase [36].  Niemann-
Pick disease, Type A is caused by a deficiency of acid sphingomyelinase with the observation of 
excess sphingomyelin and cholesterol in the liver as well as increased GM2 and GM3 
gangliosides in the brain [37].  Krabbe’s disease is the result of an accumulation of 
galactosylceramide due to a deficit in galactocerebroside β-galactosidase activity [38]. 
1.1.3 Morquio Disease, Type B 
Morquio disease, type B, or Morquio B, is a systemic bone disease also caused by a 
deficiency of β-galactosidase; however it is due to a different mutation than those that cause 
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GM1 gangliosidosis [39]. The affected patients’ most obvious symptom is spondyloepiphyseal 
dysplasia, which includes a shorter stature, protrusion of sternum, odontoid hypoplasia, and 
severe inward slanting of the thigh.  It is an autosomal recessive disease where the cleavage of 
β-linked galactose residue of keratan sulfate is impaired [40] resulting in the accumulation of 
either type of keratan sulfate (KS1 or KS2) [41].  Despite the buildup of keratan sulfate, patients 
are typically of normal intelligence but may show some neuropathological abnormalities.  This 
is thought to be due to the brain not being the primary site of storage for these molecules [41]. 
1.1.4 Galactosialidosis 
Galactosialidosis is a lysosomal storage disorder that is caused by a deficiency in a 
“protective protein” (PPCA), which has cathepsin A and deamidase properties [40, 42].  It also 
forms a complex with β-galactosidase and neuraminidase.   The lack of this protective protein 
and complex formation leads to rapid degradation of the β-galactosidase and neuraminidase 
enzymes [40, 43] and a subsequent accumulation of sialyloligosaccharides, oligosaccaharides 
attached to sialic acid residues [40].  Galactosialidosis is considered a secondary β-galactosidase 
deficiency because the lack of enzyme activity is not directly caused by a mutation in the gene 
encoding the lysosomal enzyme [41]. 
1.2 Gangliosides 
Klenk named phosphorus-free glycosphingolipids containing sialic acids, gangliosides 
[44].  He first isolated these compounds from bovine brains in 1942.   Glycosphingolipids consist 
of a sphingosine backbone and a glycosolated ceramide moiety.  The gangliosides are a special 
class of glycosphingolipids [45].  Gangliosides are derived from lactosylceramide in the Golgi 
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and the biosynthesis is catalyzed by glycotransferases [46].   The carbohydrate chain attached 
to the ceramide moiety determines the type of ganglioside.  GM1 gangliosides have a terminal 
galactose [44].   
Gangliosides are found in all animal cell membranes however they are most common in 
neuron plasma membranes [47].  There have been at least 12 different types of gangliosides 
identified in an adult human’s brain and four of these make up approximately 90% of the total.  
Gangliosides have a hydrophobic ceramide moiety that is attached to the membrane and one 
or more hydrophilic oligosaccharide chains that extend from the cell membrane into the 
extracellular matrix.  While the function of gangliosides is not fully known, this hydrophilic end 
has been reported as a potential binding site for viruses and bacterial toxins or a co-receptor 
for hormones [35].  Other functions include cell adhesion and signal transduction [48].   
The degradation of gangliosides has been studied in great detail due to the investigation 
of diseases involving their accumulation in the lysosome.  Upon the initiation of cellular 
recycling, gangliosides are pulled from outside the cell into the lysosome to be degraded.  Here, 
the hydrophobic end, that contains the sugars of the molecule, is degraded first.  The sugars are 
removed by hydrolases [35] and can then exit the lysosome and be further degraded or utilized 
in salvage processes [46].  Failure to remove this terminal molecule results in an excessive 
accumulation of the specific ganglioside and the lysosome swells impairing cell function. 
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1.3 GLB1, the structural gene for β-galactosidase 
Human GM1 gangliosidosis is caused by mutations in the β-galactosidase (GLB1) gene.  
The gene is located on chromosome 3 (HSA3) [49-52] and spans approximately 100.59 kb [53, 
54].  Alternative splicing of its 16 exons [54] produces at least two different mRNA molecules 
[55];  a 2.5 kb transcript encodes for the “classic” β-galactosidase protein and a minor 2 kb 
transcript encodes a β-galactosidase related protein, elastin binding protein (EPB), that is 
actively transcribed in fibroblasts [55, 56].  A 34 bp 5’UTR, 2031 bp coding sequence, and 314 
bp 3’UTR make up the processed mRNA with the first methionine codon beginning at the 35
th
 
nucleotide of the transcript.  This translates to 677 amino acid residues [53] resulting in an 88 
kDa precursor protein that is subsequently processed into a 64 kDa mature enzyme [43, 57].   
1.3.1 Function of β-galactosidase 
  The primary protein coded for by GLB1 is β-galactosidase, a family 35 glycosyl hydrolase 
[58].  After it is processed into its mature form, β-galactosidase associates with its protective 
protein, PPCA, and α-neuraminidase allowing β-galactosidase to be protected from rapid 
proteolysis in the lysosome [59].  Functional GLB1 produces β-galactosidase that cleaves the 
terminal galactose of the oligosaccharide moiety of GM1 gangliosides and other galactose 
containing molecules (Figure 1) [14, 60]. The alternative splice variant codes for elastin binding 
protein (EBP) [55], which assists in the assembly of elastic fibers in the extra cellular matrix [61]. 
Loss of function of the protein causes the decreased cleavage of terminal galactose 
molecules.  With this, there is a subsequent build-up of the GM1 ganglioside and other 
molecules containing terminal galactose moieties.  β-Galactosidase is also involved in 
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degradation of keratan sulfates and glycoprotein-derived oligosaccharides.  Although these 
mechanisms have not been as thoroughly studied as the degradation of GM1 ganglioside, they 
are still important functions, and without the removal of keratan sulfates, Morquio B disease is 
a potential outcome. In some cases, the genetic lesions that lead to GM1 gangliosidosis also 
involve EBP.  A decrease in elastin deposition occurs in GM1 gangliosidosis patients [61]. 
1.4 Mapping 
As a scientific community, we are still discovering the function of many genes and the 
biochemical pathways they influence.  The biological mechanisms behind some simple, single 
gene phenotypes as well as the interactions between more complex gene systems are still 
unknown.  By careful experimental design, we are able to target the traits of interest and 
expand upon the knowledge of biological mechanisms.  The advances in marker types and 
mapping techniques have helped bridge the gap between phenotype and genotype. 
The observation of co-inheritance between phenotypes was first used to determine 
relative location of the genes to one another within the genome [62].  Later, proteins and 
enzymes in blood were used as genetic markers to further enhance the ability to map by 
linkage genes controlling traits.  Restriction fragment length polymorphisms (RFLPs) and 
microsatellites were widely used in genetic studies and for building genetic maps in humans 
and animals.  [63].  Microsatellites, which are short tandem repetitive sequences that vary in 
number between individuals, soon became the marker of choice for constructing maps because 
of their ease of use and decreased number of families needed to make the map [64].  Currently, 
single nucleotide polymorphisms (SNP) are the preferred marker for many mapping 
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experiments, both large and smaller scale. As the name implies, SNP are single base pair 
changes in the genome at a known location where there are generally two possible bases.  The 
rapid advancement of SNP technology platforms has allowed for the analysis of thousands of 
markers with relatively even coverage across the genome, aiding in the ability to more precisely 
map traits of interest. 
Linkage disequilibrium (LD), the non-random assortment of alleles, can be utilized in 
mapping of simple recessive traits.  When there is a non-random distribution of alleles at a 
marker in a case group and a control group, we can say that a marker is in high LD with the 
locus in question.  For example, in the case of a simple recessive disease trait, if the affected 
individuals are all homozygous for a certain allele at a marker and the control individuals are 
homozygous for the opposite allele at the same marker, we can say that this marker is in high 
LD with the disease locus.   
By using this concept, we can move away from following the inheritance of large 
chromosomal sections through a pedigree.  This allows unrelated individuals to be used in a 
mapping population by instead looking for areas of historical recombination events that took 
place prior to the generations of the individuals in the mapping population, but that still share 
regions of a chromosome.  The increased number of markers used takes advantage of these 
recombination events and narrows the areas of homozygosity allowing for more determinate 
mapping. 
In 1987, Lander and Botstein [65] presented the idea of mapping recessive disease loci 
using homozygosity of markers.  This approach originally used restriction fragment length 
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polymorphism (RFLP) makers scattered throughout the genome to distinguish different regions 
of homozygous by descent genotypes in individuals of consanguineous matings.  By doing so, 
the probability of a disease locus being within a defined/specific region can be calculated. 
Homozygosity mapping has been a useful method to increase the power of disease 
mapping studies.  This approach allows for refinement of the region on the chromosome that 
needs to be examined for a disease locus.  The idea of homozygosity of markers can be 
translated from RFLP to SNP markers in that areas of the chromosome that are homozgygous 
for all markers in all affected individuals is still the indicator that the disease locus is located 
within this region. 
To statistically test this concept of deviation from Hardy-Weinberg Equilibrium, a 
genome wide association (GWA) approach is used.  The use of genome wide association 
techniques was reviewed by Hirschhorn and Daly [66].  The concept underlying case/control 
GWA studies is that each SNP is tested for an association between its genotype and the 
phenotype, where a case is defined as an individual with the phenotype of interest and a 
control is a normal individual.  A good control is of similar genotype at all other loci, other than 
the one of interest.  A GWA analysis compares the allele frequency present in the case 
population to that in the control population. 
Currently, this SNP-based approach to mapping is the foundation of most genetic 
disease studies in both humans and animals.  Charlier, et al. [67] used SNP based association to 
map five recessive defects in cattle and was able to fine map and identify causative mutations 
in three of these diseases.  Mapping of disease loci this way can allow a more direct method to 
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mutation discovery and therefore diagnostic assay development.  The speed of discovery with 
SNPs and GWA analysis is far faster than other forms of mapping and requires fewer individuals 
than previous forms as well.  This technique takes advantage of the lack of family structure by 
utilizing linkage disequilibrium to refine areas of significant associations of genotype at markers 
to phenotype. 
1.5 GM1 gangliosidosis in sheep 
Ovine GM1 gangliosidosis was first described following the production of affected lambs 
after breeding rams were purchased from the same source for two years in a row [68].  Due to 
the level of inbreeding, normal affection status of the parents, and the presence of both male 
and female affected lambs, it was suggested the disease was inherited in an autosomal 
recessive manner [23].  Prieur, et al. later demonstrated that the disease has an autosomal 
recessive inheritance pattern based on a quantitative analysis of planned matings [69].  
Although there was an abnormal distribution of males and females for an autosomal recessive 
inheritance pattern, small sample size was recognized as a potential cause. 
Pruier, Murnane, and Ahern-Rindell have described the pathology of the ovine disease 
in depth [23, 27, 68, 70-73].  The cytoplasm of neuronal cells has a foamy appearance and has 
characteristic vacuoles present.  The level of β-galactosidase activity in affected lambs is 
approximately 5% of homozygous normal animals.  Obligate heterozygous animals have 
approximately half of the normal β-galactosidase activity of normal animals due to a gene 




The decreased level of β-galactosidase in affected lambs causes a vast increase in GM1 
gangliosides in the brain and central nervous system.  This buildup causes an enlargement of 
the neurons and some cells have displaced nuclei.  There is excess storage in other tissues as 
well, but the severity is not as high.  Retina, ganglia of various organs, heart Purkinje fibers, 
liver, kidney, histiocytes of the ileum, mesenteric and hilar lymph nodes all show lesions 
associated with ganglioside accumulation [73]. 
Affected sheep have a deficiency of β-galactosidase as well as α-neuraminidase [23].  
Humans with deficiencies of both of these enzymes are diagnosed as having galactosialidosis 
[40].  However, based on the lack of increase in β-galactosidase activity when fibroblasts from 
affected sheep are incubated with leupeptin, the ovine disease has been classified as 
gangliosidosis [23].  Human galactosialidosis fibroblasts show an elevation in β-galactosidase 
when treated leupeptin, therefore showing that the compromised β-galactosidase activity in 
sheep is not due a similar etiology [74].  
Hartley and Kater reported a lamb that was affected with a similar deficiency in New 
Zealand [75].  In 1991, Murnane, et al. examined the similarities between the lamb reported in 
New Zealand and the lambs previously reported in their work [76].  The central nervous tissues 
of the New Zealand lamb had an almost identical lectin-binding pattern as their lambs.  
Therefore, they concluded that the New Zealand lamb was most likely also affected with GM1 
gangliosidosis. 
Murnane, et al. also reported that affected lambs already show signs of GM1 
gangliosidosis at four months gestation [77].  A recipient ewe that was carrying triplets 
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designated for study died unexpectedly approximately one month prior to lambing.  Beta-
galactosidase activity was assessed for all three fetuses.  As a result, two of the three were 
classified as heterozygotes and the third as affected based on the low circulating levels of β-
galactosidase.  Upon further investigation, the affected fetus was already showing other signs 
of GM1 gangliosidosis pathology.  This was an important finding because it suggests that 
prenatal therapy may have some potential for treating potentially affected fetuses. 
Skelly, et al. [29] also reported a type of ovine GM1 gangliosidosis that is similar to those 
reported by Ahern-Rindell, Murnane, and Prieur.  Lambs of the same sire showed symptoms of 
ataxia in the hind limbs, opisthotonus, were unable to stand and ultimately became 
unresponsive and blind.  Necropsy of these lambs exposed diffuse encephalopathy.  Ballooned 
neurons were seen in the brain and spinal cord.  The lambs had a 90% deficiency of β-
galactosidase activity; however, unlike the previously reported GM1 gangliosidosis lambs they 
did not have a deficiency of α-neuraminidase.  Based on these data, it was concluded that these 
lambs exhibited a novel form of ovine GM1 gangliosidosis that was most similar to the infantile 
form of the human disease. 
Studying these sheep can aid in understanding the progression of the disease and 
hopefully increase knowledge of pathologies associated with deficiencies of β-galactosidase.  
However, to do so efficiently, knowledge of genotypic status prior to symptom onset would be 
greatly beneficial.  Advances in treatment of human patients may be attained by characterizing 
the genetic lesion underlying ovine GM1 gangliosidosis and using the information to identify 
affected individuals at a young age.  
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Chapter 2: Molecular Genetic Characterization of Ovine GM1 Gangliosidosis: 
An Animal Model 
2.1 Background 
Animal models of human diseases can serve a valuable purpose by creating 
opportunities to study treatments and therapies of homologous human disorders.  Although 
laboratory animals such as mice and rats may be convenient from a facilities and management 
perspective, larger animals may be preferred due to similarities in anatomy, developmental 
timeline, and pathology as compared to humans.  Sheep and other non-laboratory animals have 
been used as models for retinal degeneration [2], cardiovascular disease [3], congestive heart 
failure [3-5], cardiomyopathy [6], muscular dystrophy [7], Parkinson’s disease [8], and 
hemophilia [1], among other diseases. 
GM1 gangliosidosis is a lysosomal storage disorder.  There are three types of human 
GM1 gangliosidosis that differ in age of disease onset.  Symptoms of infantile (Type I) appear 
between birth and approximately 6 months of age. Progression of the disease is rapid with 
death of affected individuals occurring by two years of age.  Type II has a later onset with 
symptoms developing between 7 months and 3 years of age.  Type III, the adult form, has a late 
onset of between 3 and 30 years old [26].  Most animal models of the disease are most similar 
to the Type II form of the disease [16, 22, 27, 28]. GM1 gangliosidosis has been described in 
cattle [15-17], cats [18-20], dogs [21, 22] and sheep [23].  A mouse model has been generated 
for use in research [25].  These species all have similar symptoms with the most prominent 
being a gross deficiency of β-galactosidase and the subsequent buildup of GM1 gangliosides.  
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These accumulations in the brain lead to the display of neurological symptoms and eventually 
cause the death of the individual. 
Sheep with GM1 gangliosidosis begin exhibiting symptoms at approximately four 
months of age and have approximately 5% β-galactosidase activity of normal sheep [23, 27, 68, 
70-73].  This decrease in β-galactosidase causes an increase of GM1 gangliosides in the brain 
and some other tissues [73].  Affected lambs also have a deficiency of α-neuraminidase but do 
not have an increase in β-galactosidase activity after treatment with leupeptin.  Because of this, 
they are diagnosed with GM1 gangliosidosis [23]. 
The purpose of this study was to characterize the causative DNA mutation underlying 
ovine GM1 gangliosidosis and use the resulting information to design a DNA-based diagnostic 
that can be used for screening animals prior to the onset of disease. The identification of 
affected animals prior to the appearance of clinical symptoms will provide an opportunity to 
investigate therapies and treatments of GM1 gangliosidosis. 
2.2 Materials and methods 
2.2.1 Animals  
Samples used for this study were submitted by Dr. Larry Holler of South Dakota State 
University.  Whole blood samples were collected using EDTA anticoagulant from affected lambs 
and putative homozygous normal sheep.  Progeny testing was used to determine an animal’s 
potential to be homozygous normal (i.e., individuals failing to produce affected offspring after 
repeated matings to known heterozygotes).  DNA was extracted using the salting out method 
17 
 
[78]. Following extraction, genomic DNA was quantified by spectrophotometry using a 
NanoDrop instrument (Thermo Fisher Scientific, Inc., Wilmington, DE). 
2.2.2 SNP Genotyping, Data Analysis, and Mapping 
One microgram of each individual’s DNA was submitted to GeneSeek (Neogen 
Corporation, Lincoln, NE) for genotyping on the Ovine SNP50 Genotyping BeadChip (Illumina, 
Inc., San Diego, CA).  Genotype data were analyzed by Genome Wide Association (GWA) in 
PLINK [79].  Genotype data were pruned by removing markers with a minor allele frequency 
(MAF) of less than 1% (--maf 0.01) and genotyping frequency of less than 90% (--geno 0.1).  
Genotype data for individuals with less than 85% genotyped loci were also removed.  Standard 
case/control association analysis (--assoc) and association analysis with 10,000 permutations (--
mperm) were performed using the remaining markers.  Homozygosity analysis (--homozyg) was 
used to identify overlapping regions of homozygosity shared by affected animals based on GWA 
results.  The Virtual Sheep Genome [80] and functional gene annotation were used to select 
positional candidate genes for sequencing. 
2.2.3 Mutation detection 
Total RNA was extracted from cerebral tissue of an affected lamb.  Extraction was 
performed according to manufacturer instructions using TRIzol® reagent (Invitrogen™, Life 
Technologies Corporation, Grand Island, NY).  RNA was quantified using a NanoDrop instrument 
(Thermo Fisher Scientific, Inc., Wilmington, DE) and quality was assessed by electrophoresis in a 
1.2% agarose 1X MOPS gel.  Ethidium bromide staining and exposure to UV light was used to 
visualize the RNA. 
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Complementary DNA (cDNA) was synthesized in a 20 µL reaction by first combining 2 µg 
total RNA, 0.5 µM random decamers, and 0.5 mM dNTPs in a total volume of 13 µL; the 
combined mixture was then incubated at 65°C for 5 minutes.  First strand buffer, DTT at 5 μM, 
RNase Out at 2 units/µL, and Superscript III reverse transcriptase at 10 units/μL were included 
and the mixture was incubated again for 5 minutes at 25°C, 2 hours at 50°C, and 15 minutes at 
10°C.  DNase/RNase free water was added to dilute total volume to approximately 100 µL. 
A consensus sequence generated using BLAST [81] was used to design primers in Primer 
Designer v2.0 (Scientific and Educational Software, Cary, NC).  All primers (Table 1) were 
synthesized by Integrated DNA Technologies (Coralville, IA).  The cDNA was amplified in 20 µL 
reactions including 2.5 units HotStarTaq DNA Polymerase (Qiagen, Valencia, CA), primers at 
0.5μM, deoxynucleotide triphosphates (dNTPs) at 200μM, and 1X PCR buffer solution (included 
with polymerase).  The thermocycler was programmed with a standard three-step program.  To 
verify quality, PCR products were separated via electrophoresis of a 1% agarose 0.5x TBE gel 
stained with ethidium bromide. 
PCR products were treated with ExoSAP-IT (Affymetrix, Inc., Santa Clara, CA) to prevent 
residual primers and unincorporated dNTPs from interfering with sequencing reactions.  Four 
µL ExoSAP-IT (1:12 dilution) was added to 10 µL of PCR product.  The reaction was incubated for 
45 minutes at 37°C and an additional 15 minutes at 80°C.  Dye-terminator Sanger sequencing 
was performed using 2 µL of ExoSAP-IT treated PCR product; 0.25 µL Big Dye® (Applied 
Biosystems, Life Technologies Corporation, Grand Island, NY), 0.08 µL Big Dye® dGTP (Applied 
Biosystems), 3.62 µL Sanger Sequencing Buffer, and 0.525 µL 10 µM primer are included to 
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make an 8 µL reaction.  Samples were heated to 96°C for initial denaturing then cycled 96°C for 
15 seconds, 53°C for 15 seconds, and 60°C for 3 minutes for 55 cycles.  After the final cycle, the 
sample was incubated at 60°C for 10 minutes. 
Ready-to-load samples were delivered to the W. M. Keck Center for Comparative and 
Functional Genomics at the University of Illinois and run on an AB 3730xl DNA Analyzer (Applied 
Biosystems).  Data were analyzed in CodonCode Aligner software (CodonCode Corporation, 
Dedham, MA).  Sequence variants within protein coding regions were examined using SIFT [82] 
and PolyPhen [83] web-based protein variation predictors.   
2.2.4 Completing Genomic Sequence of GLB1 
Agar stabs received from CHORI BACPAC Resource Center (Children’s Hospital Oakland 
Research Institute, Oakland, CA) were streaked on chloramphenicol 2x LB media agar plates and 
grown at 37°C overnight.  Colonies were picked (2 per BAC) and cultured in 5mL cultures of 2x 
LB media with 1μg/mL chloramphenicol for 16 hours at 37°C and 250 rpm.  BAC DNA for 
screening was isolated using the Perfectprep BAC96 kit (5 Prime). 
PCR screening for the genes up- (CCR4) and down- (TMPPE) stream, as well as GLB1 
exons 2, 6, and 14 was performed.  Primers were designed in Primer Designer v2.0 and PCR was 
performed in 20 µL reactions with a standard 3-step program as described previously.  Criteria 
for selection involved inclusion of all PCR amplicons and proposed position over region of 
interest. 
 Three-milliliter cultures of agar stabs were grown in 2x LB media overnight at 37°C and 
250 rpm with 1μg/mL chloramphenicol. Three milliliter cultures from plucked colonies were 
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grown overnight in 2x LB media with 1μg/mL chloramphenicol at 37°C and 250 rpm, and 1 mL 
of each culture was used to inoculate fifty milliliter cultures grown at the same conditions for 
BAC DNA isolation. 
Purified BAC DNA was extracted using the Epicentre BACMax DNA purification kit 
(Illumina).  Fifty-milliliter cultures were grown to A600 of 3-4 and kit isolation procedures were 
followed.  DNA was submitted to the Keck Center and the library was constructed with the 
TruSeq DNA Sample Prep kit (Illumina) then sequenced using the Illumina® MiSeq instrument 
(Illumina).  The resulting sequence was assembled by the Keck Center Bioinformatics Team.  
Using resulting contigs, sections of repetitive sequence and gaps between contigs were filled 
using direct sequencing and assembled in CodonCode Aligner. 
2.2.5 Assay Development 
A PCR-RFLP diagnostic assay was developed based on differences in restriction enzyme 
recognition site created by the mutation.  PCR amplification was performed in 20 μL reactions 
with each reaction including Qiagen HotStarTaq DNA Polymerase at a rate of 2.5 units/μL.  
Primers are included at 0.5μM and dNTPs are included at 200μM.  10x PCR buffer solution 
(included with Taq) is included at 1x.  29 total cycles with an annealing temperature of 55°C and 
an extension time of 1 minute, 15 seconds are used.  Restriction enzyme digest occurs with Aci I 
(5 units/30 μL reaction, New England Biolabs, Inc., Ipswich, MA).  PCR products are separated 




2.3.1 SNP Genotyping, Data Analysis, and Mapping 
Implementation of quality control and polymorphism thresholds for genotype data 
resulted in the culling of 5,976 SNPs; thus for all 17 individuals (seven cases and ten controls) 
genotyped, 46,437 markers were used for association analysis.  Of the ten most significant 
associations there was one marker located on each of sheep chromosomes 5, 17 and 23, with 
the remaining seven located on chromosome 19 (OAR19) (Table 2; Figure 2).  The most 
significant association was detected with the marker OAR17_37111029.1, on OAR17.  Although 
this marker had the highest association, examination of genotypes in the affected lambs 
revealed that two of seven were heterozygous.  Further investigation of the single marker 
associations on OAR5 and OAR23 showed similar results.  For the SNP on OAR5, all three 
genotypes were present within the group of affected lambs.  In contrast, the affected lambs 
were all homozygous for the marker located on OAR23, however four of the putative 
homozygous controls were heterozygous.  
Due to the number of markers with highly significant associations (p<10
-6
) located on 
OAR19, these markers were also more closely examined.  The marker showing the most 
significant association on OAR19, OAR19_8302232.1, along with OAR19_9225668.1, was 
homozygous in all affected animals, with the three and four of the control sheep being 
heterozygous, respectively.  Three SNPs, although having the third most significant association, 
were heterozygous in one affected lamb and two putative normal homozygotes.  The remaining 
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of the top ten SNPs were also heterozygous in one affected lamb as well as three of the control 
sheep. 
Even though many of the significantly associated markers on OAR19 were not consistent 
with the putative known genotypes of the individuals, the large number of associated SNPs on 
this chromosome provided reason to perform a homozygosity analysis for this chromosome.  
Results of the analysis indicated that all affected lambs were homozygous for markers between 
7.2 and 9.4 Mb (Figure 3A).  Furthermore, comparative genome analysis, using the human 
(Build 36.3) and cattle (Btau 3.1) genome assemblies, indicates that the region is orthologous to 
human chromosome 3 containing the candidate gene GLB1 (Figure 3B).   
2.3.2 GLB1 Mutation Detection 
The absence of either a complete mRNA or genomic DNA sequence for sheep GLB1 
required the in silico assembly of a consensus ovine sequence prior to mutation detection.  The 
bovine reference mRNA sequence (GenBank accession NM_001035043.1) was used to perform 
a BLAST query of the GenBank, EMBL, and DDBJ expressed sequence tag (EST) database to 
identify all potential ovine sequences.  Twenty-six sequences were recognized as belonging to 
the orthologous sheep GLB1 transcript (Appendix Figure 1).  The alignment of the sheep EST 
sequences generated a consensus ovine GLB1 sequence of 2,346 bp (Appendix Figure 2).  
Translation of the consensus sequence indicated the putative initiation codon was located at 
nucleotide position 60 and the predicted termination codon at position 1,998.   This leaves an 
estimated 59 bp and 348 bp of 5’ and 3’ untranslated regions, respectively.  A consensus 
polyadenylation signal is predicted between nucleotides 2328 and 2333 of the putative 
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transcript.  The corresponding translated protein is composed of 646 amino acids (Appendix 
Figure 3). 
Using the cDNA generated from cerebrum total RNA of an affected lamb, four 
overlapping fragments corresponding to 90.5% of the ovine mRNA sequence were successfully 
amplified.  Sequence analysis revealed a single guanine to thymine base pair substitution within 
exon 6 of ovine GLB1.  This transversion mutation results in a cysteine to phenylalanine 
nonsynonymous amino acid substitution.  No other sequence variation was identified. Analyses 
of this substitution using SIFT and PolyPhen predict that the function of the resulting protein 
would be compromised.  Furthermore, comparison of partial protein sequences across several 
species illustrates conservation of the cysteine residue at this position (Figure 4). 
2.3.3 Completing Genomic Sequence of GLB1 
 Sheep BAC end sequences generated by Dalrymple, et al. [80] were used to assist in the 
identification of BACs potentially containing the entire sheep GLB1 gene.  A BLAST query of BAC 
end sequences selected from the Virtual Sheep Genome confirmed similarity to bovine 
chromosome 22 surrounding GLB1.  PCR screening of selected BACs showed that all BACs 
contained the desired region.  The BAC clone CH243_119J20 was selected for sequencing based 
on the estimated location of GLB1 within the cloned genomic fragment; alignment of the BAC 
end sequence BLAST search results suggested GLB1 was located closest to the middle of the 
cloned DNA.  Sequencing of clone 119J20 on the MiSeq instrument resulted in 8,201,678 reads.  
After removal of E. coli reads, approximately 5 million reads remained.  Seven contigs were 
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assembled from the remaining data with GLB1 being contained in two.  After direct sequencing, 
these two were joined and used to predict positions of exons (Appendix Figure 4; Table 3). 
2.3.4 Diagnostic Assay Development 
The guanine to thymine transversion induces the loss of an AciI restriction enzyme 
recognition sequence, CCGC (wild-type) versus CCTC (affected).  Oligonucleotide primers were 
designed to amplify a 314 bp fragment and, when treated with the restriction endonuclease, 
the wild type allele leaves two fragments of 201 and 113 base pairs (Figure 5).  Sheep of known 
status from the flock at South Dakota State University were genotyped in order to validate the 
assay. 
2.4 Discussion 
2.4.1 SNP Genotyping, Data Analysis, and Mapping 
The use of high density SNP platforms has improved the ability of scientists to evaluate 
recessive genetic diseases.  Previously, a large number of related individuals spanning multiple 
generations and with known pedigrees were required to map diseases.  Using the OvineSNP50 
Bead Chip and GWA techniques, the ovine GM1 gangliosidosis disease locus was mapped with 
only seven affected animals with little to no known pedigree information required in the 
analysis.  GWA analysis maps the disease locus to a region on OAR19.  Following homozygosity 
analysis, it was observed that all affected animals were homozygous for markers between 7.2 




Genome resources for some species are more advanced than others.  Although 
significant improvements are made continually, the sheep genome is still in its infancy.  
Typically, SNP data is analyzed and suitable candidate genes within the region are selected for 
further analysis based on physiological symptoms, relevance to gene function, and location in 
relationship to map position.  Because the sheep genome lacked both sequence information 
and annotation in this region, a comparative mapping approach using the Virtual Sheep 
Genome [80] and relationship to both the human and bovine reference genomes was examined 
for further information.  We were able to select GLB1 as a positional candidate gene. 
The diagnosis of GM1 gangliosidosis with the similarity of symptoms between the 
species and the gross accumulation of GM1 gangliosides in affected sheep indicated a mutation 
in GLB1 as seen in other species was likely [28, 41, 84, 85]. is cause of extra attention [23].  
While the most likely candidate for such pathology is a disruption of GLB1, the deficiency of α-
neuraminidase that accompanies the lack of β-galactosidase and buildup of GM1 gangliosides in 
diseased sheep gives reason to map the disease locus.  
2.4.2 Sequencing 
In human brain tissue, GLB1 expression is highly abundant, suggesting that brain tissue 
from an affected lamb would be ideal for RNA extraction [86].  By amplifying and sequencing 
the brain cDNA, we were determined the coding sequence of sheep GLB1.  The cDNA sequence 
of affected sheep possessed a guanine to thymine base pair substitution with the altered base 
being the second base of a codon.  Typically, a change in the second base in a codon will modify 
the amino acid residue. 
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The codon, originally a cysteine codon, becomes a phenylalanine residue, and although 
the both are of neutral charge, the differences in polarity and functional groups insinuate that 
the exchange will be damaging.  Cysteine residues contain a sulfhydryl group and form disulfide 
bonds with other cysteine residues.  This influences the folding of the polypeptide strand and 
thus the structure and stability of the molecule.  In the human β-galactosidase protein, Cys-230 
forms a disulfide bond with Cys-195 (predicted -229 and -194 in sheep sequence) [87].  
Therefore, the substitution of ovine Cys-229 would likely cause an improperly folded protein 
due to lack of a disulfide bond.   
The triosephosphate isomerase (TIM) barrel domain that is characteristic of glycosyl 
hydorlases spans the first 359 amino acid residues of human β-galactosidase [87].  The altered 
residue as well as the catalytic residues of human β-galactosidase Glu-188 and -268, are located 
in the TIM barrel [87, 88].  Because is the catalytic domain of the protein, it is expected that a 
substitution of amino acid of the magnitude as seen in the affected lambs would likely be the 
causal change.  Alignment of predicted ovine GLB1 to other species shows that the Cys-residue 
is highly conserved (Figure 4).  The results from SIFT and PolyPhen agree with the notion that 
the altered amino acid is not tolerated and results in a nonfunctional protein. 
Differences in the number of residues between human and ovine amino acid sequences 
are noted.  The first discrepancy is the result of an additional codon in the human sequence 
between the third and fourth ovine residues.  This results in a shift of the alignment to account 
for the high conservation downstream leaving a gap in the ovine sequence.  The other deviation 
between the two is the additional 30 residues present in the human sequence after the location 
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of the predicted ovine stop codon.  Neither of these discrepancies is part of highly conserved 
domains across species and therefore is not of high concern. 
2.4.3 Assay Development 
Treatments and therapies for genetic diseases are scarce in most species.  Many 
livestock producers simply cull carrier animals due to the potential for loss.  However, human 
genetic diseases can be further researched via animal models that have similar phenotypes 
caused by similar genetic lesions.  The sheep can be an effective model for human disease due 
to its relative mature body weight and similar size of internal organs.  Affected lambs can be 
used to research treatments and therapies for human GM1 gangliosidosis patients and carrier 
animals can be used to continue production of said affected sheep.  As a result, the assay 
designed is useful for identifying heterozygous sheep for breeding decisions and affected 
animals prior to death for symptom observation. 
The PCR-RFLP assay designed for genotyping sheep is a simple diagnostic via DNA.  In 
total, 1664 individuals have been genotyped using the developed assay.  The assay was in 
agreement with phenotype, and all lambs that were genotyped homozygous affected 
eventually showed symptoms of disease pathology.  Conversely, all lambs shown to be 
homozygous for the normal allele or heterozygous did not exhibit GM1 gangliosidosis 
symptoms. 
2.5 Conclusions 
Lysosomal storage disorders are a broad category of diseases with similar biochemical 
backgrounds.  These disorders have proven to be difficult to treat and often result in death of 
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the affected individual, especially if onset is early in life.  Using animal models like the sheep 
used in this study, progress can be made not only in research of GM1 gangliosidosis, but in 
other lysosomal storage disorders too. 
The phenotype of affected lambs diagnosed as GM1 gangliosidosis gives indication that 
GLB1 is non-functional in said sheep.  The genetic data represents an association between the 
phenotype and markers on OAR19 between 7.2 and 9.4 Mb.  Comparative maps indicate that 
ovine GLB1 lies in that area, and sequencing data proves that a mutation causing deleterious 
effects is present. 
In conclusion, the purposes of this study were met by finding the causative mutation of 
ovine GM1 gangliosidosis, a G to T base pair substitution in exon 6 of ovine GLB1.  The mutation 
was then used to design and PCR-RFLP assay in order to identify lambs by genotype before the 
symptoms of the disease may be shown.  These lambs are to be identified and used to develop 
therapies for use in human medicine. 
 Figures and Tables 
Figure 1.  Structure of GM1, GM2, and GM3 ganglioside.  
galactose of the oligosaccharide moiety from GM1 
 








Figure 2.  Manhattan plot of standard case/control GWA analysis with 10,000 permutations.  The –log10(p-value) is plotted on the 
y-axis against the position of each SNP within the genome on the x-axis.  The purple horizontal line represents a significance 
threshold of p < 0.01. 
  
Figure 3.  Homozygosity analysis of the GM1 Gangliosidosis
lambs are homozygous for all SNPs between 7.2 and 9.4 Mb (grey box).  This coincides with the area of significant association
the GWA analysis.  B)  The alignment of the human (top) and bovine (bottom) genomes to the ovine genome (7.4 to 8 Mb) shows 
that GLB1 in each species (red asterisks) corresponds to the region of interest on OAR19 (7.4 to 8 Mb, black box).
-associated region on OAR19 in affected lambs
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Figure 4.  Alignment of GLB1 amino acid sequence around predicted mutation to other species.  The Cys residue (shown in box) is 
highly conserved at this position. 
Mouse YLRFLVHRFRYHLGNDVILFTTDGASEKMLKCGTLQDLYATVDFGTGNNI 
Rat YLRFLEHRFRYHLGNDIILFTTDGAAEKLLKCGTLQDLYATVDFGTTGNI 
Affected lamb       YLRFLQKRFQDHLGEDVLLFTTDGVNEEFLQFGALQGLYATVDFSTGSNL 
Ovine  YLRFLQKRFQDHLGEDVLLFTTDGVNEEFLQCGALQGLYATVDFSTGSXL 
Bovine   YLRFLQKRFHDHLGEDVLLFTTDGVNERLLQCGALQGLYATVDFSPGTNL 
Dog     YLRFLQKLFHHHLGNDVLLFTTDGANEKFLQCGALQGLYATVDFGPGANI 
Human YLRFLQKRFRHHLGDDVVLFTTDGAHKTFLKCGALQGLYTTVDFGTGSNI 
Zebrafish YMRHLSQLFRFYLGEEAVLFTTDGAGLGYLKCGSLQGLYATVDFGPGANV 





Figure 5.  Electrophoresis of PCR-RFLP diagnostic.  In a 1.6% agarose gel, from left to right, two 
carrier individuals, an affected, a homozygous normal, an affected, a homozygous normal, and 
a negative control, are separated next to a 100bp ladder.  The larger 314 bp fragment can be 





Table 1.  Primers used for PCR amplification and direct sequencing. 































Table 2.  Markers exhibiting highest statistical association with affection status. 
Marker Chromosome Position P 
OAR17_37111029.1 17 37111029 0.0005999 
OAR19_8302232.1 19 8302232 0.003 
OAR19_4624345.1 19 4624345 0.008799 
s58656.1 19 10218656 0.008799 
OAR19_12511657.1 19 12511657 0.008799 
OAR19_9225668.1 19 9225668 0.0205 
s18696.1 23 24251647 0.0205 
OAR5_86386899.1 5 86386899 0.0433 
s28559.1 19 11401883 0.05929 
OAR19_11692436.1 19 11692436 0.05929 
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Exon 1 13648-13778 1-131 131 
Exon 2 36654-36823 132-301 170 
Exon 3 38463-38613 302-452 151 
Exon 4 39153-39213 453-513 61 
Exon 5 40396-40490 514-608 95 
Exon 6 48042-48222 609-789 181 
Exon 7 53385-53443 790-848 59 
Exon 8 55154-55275 849-970 122 
Exon 9 55386-55426 971-1011 41 
Exon 10 57613-57725 1012-1124 113 
Exon 11 80916-80990 1125-1199 75 
Exon 12 83235-83324 1200-1289 90 
Exon 13 85975-86088 1290-1403 114 
Exon 14 89049-89180 1404-1535 132 
Exon 15 91056-91310 1536-1790 255 
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Appendix A:  Appendix Figures 
Appendix Figure 1.  Consensus sequence generated using BLAST query of EST database.  The 
start codon, stop codon, and poly adenylation signal have been bolded and italicized.  Single 
underlines represent forward primers and double underlines represent reverse primers.  The 






































Appendix Figure 2.  CLUSTALW alignment of ovine ESTs from BLAST query of EST database. 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ---------- ---------- ---------- ---------- ---------- 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------C GGTCCGGATT 
gi_114718270_gb  TCCGGGATGC GGTGGCTTTC CCCTTCATGA TATGCTTGCT CTTGGGGCAA 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114450604_gb  ---------- ---------- ---------- ---------- ---------- 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ---------- -----AGCCG GGGACCATGA TGTGGAACAT TTCATTCAGC 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  CCCGGGATCT GTACATGTTT ATAGGTGGCA GCAATTTTGC CTATTGGAAT 
gi_114718270_gb  ATGTAAACAT GTACATGTTT ATAGGTGGCA GCAATTTTGC CTATTGGAAT 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  TGGCACATGA GCTGGGACTG CTGGTCATCC TGAGGCCTGG ACCCTACATC 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  GGAGCAAACA CGCCCTACCA ACCACAGCCC ACCAGCTACG ACTATGATGC 
gi_114718270_gb  GGAGCAAACA CGCCCTACCA ACCACAGCCC ACCAGCTACG ACTATGATGC 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114450604_gb  ---------- ---------- ---------- ---------- ---------- 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  TGTGCAGAGT GGGACATGGG AGGATTACCT GCTTGGCTGT TGGAGAAAAA 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  CCCGCTGAGC GAGGCTGGGG ACCTCACGGA GAAGTATTTT GCTCTGCGGG 
gi_114718270_gb  CCCGCTGAGC GAGGCTGGGG ACCTCACGGA GAAGTATTTT GCTCTGCGGG 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 
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gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ATCTATTGTT CTCCGTTCTT CAGATCCAGA TTACCTTGCG GCTGTGGACA 
gi_229652641_gb  ---------- ---------- ---------- ------GGCG GCTGTGGACA 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ATATTATTCA GAAGTTTGCA AAAGTACCGG AAGGTCCTAT CCCCCCATCC 
gi_114718270_gb  ATATTATTCA GAAGTTTGCA AAAGTACCGG AAGGTCCTAT CCCCCCATCC 
gi_114744710_gb  --AGGACACC TTCCTCCAGT TTCCTGGATG GACCAAGAGG AAGCATGTGT 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114450604_gb  ---------- ---------- ---------- ---------- ------ATCA 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  AGTGGCTGGG GGTCCTTCTG CCCAAGATGA GGCCCCTCCT CTATAAGAAC 
gi_229652641_gb  AGTGGCTGGG GGTCCTTCTG CCCAAGATGA GGCCCCTCCT CTATAAGAAC 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ------TGCT CTGAAAAAGT TAAAGACGGT 
gi_114718999_gb  ACACCAAAGT TTGCATATGG AAAAGTTGCT CTGAAAAAGT TAAAGACGGT 
gi_114718270_gb  ACACCAAAGT TTGCATATGG AAAAGTTGCT CTGAAAAAGT TAAAGACGGT 
gi_114744710_gb  CTGGGCTGCT GGGCTCCTGC TTACCTGGGG CAGCAAGACC CCTACAGCCT 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- --CGACGCCG AACGGCTGCC CCGGCT-ACT 
gi_88627441_gb_  ---------- ---------- --------CG AACGGCTGCC CCGGCTGACT 
gi_88629151_gb_  ---------- ---------- --------CG AACGGCTGCC CCGGCTGACT 
gi_88620401_gb_  ---------- ---------- ---------- ---GGCTGCC CCGGCTGACT 
gi_88644845_gb_  ---------- ---------- ---------- AACGGCTGCC CCGGCTGACT 
gi_114492173_gb  ---------- ---------- ---------- CCGGGATGCC CCGGCTGACT 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---GCTGACT 
gi_280968126_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  GGAGGCCCGA TTATAACAGT GCAGGTTGAA AATGAATATG GCAGCTACTA 
gi_229652641_gb  GGAGGCCCGA TTATAACAGT GCAGGTTGAA AATGAATATG GCAGCTACTA 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---GGATGCT CTCAACATCC TGTGTCCCTC TGGACCCATA AAAAGTGTTT 
gi_88654284_gb_  GGAGGATGCT CTCAACATCC TGTGTCCCTC TGGACCCATA AAAAGTGTTT 
gi_114718999_gb  GGAGGATGCT CTCAACATCC TGTGTCCCTC TGGACCCATA AAAAGTGTTT 
gi_114718270_gb  GGAGGATGCT CTCAACATCC TGTGTCCCTC TGGACCCATA AAAAGTGTTT 
gi_114744710_gb  GGAGGAGGGG GGAGCACAGA GGCAAAGCTC GTCTCCTGAG GAGGCAGGGA 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114450604_gb  TAAAAATCAG AAAAACTTCA AATGCTTCCC TTCCAACCCT GTGGATGCCT 
 
gi_31084151_gb_  GCGGA-CC-- --GGGAGGCC CGA-AGCGGA CGGACATGCC GGGGGTCGTG 
gi_88627441_gb_  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_88629151_gb_  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_88620401_gb_  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_88644845_gb_  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_114492173_gb  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_88634142_gb_  GCGGAGCC-- --GGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_280968126_gb  ---------- --AGGAGGCC CGAGAGCGGA CGGACATGCC GGGGGTCGTG 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  TTCCTGTG-- --ATTACGAC TACTTGCGTT TCCTGCAGAA GCGTTTCCAG 
gi_229652641_gb  TTCCTGTG-- --ATTACGAC TACTTGCGTT TCCTGCAGAA GCGTTTCCAG 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ----CTTG-- --ACGTTTGT TGATGTGAAA CAGTACTTTG GATTTGTGCT 
gi_88626309_gb_  ATCCCTTG-- --ACGTTTGT TGATGTGAAA CAGTACTTTG GATTTGTGCT 
gi_88654284_gb_  ATCCCTTG-- --ACGTTTGT TGATGTGAAA CAGTACTTTG GATTTGTGCT 
gi_114718999_gb  ATCCCTTG-- --ACGTTTGT TGATGTGAAA CAGTACTTTG GATTTGTGCT 
gi_114718270_gb  ATCCCTTG-- --ACGTTTGT TGATGTGAAA CAGTACTTTG GATTTGTGCT 
gi_114744710_gb  GGTGACTG-- --TGTACAGA GGCCTCGGGC AGAGGCGGGT GTGTGCAGAC 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- -----GCGTG ACGTGCGCTA 
gi_114474748_gb  ---------- ---------- ---------- -----GCGTG ACGTGCGCTA 
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gi_31084151_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88627441_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88629151_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88620401_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88644845_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_114492173_gb  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88634142_gb_  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_280968126_gb  CGCCTCCTCG CCCTGCTGCT GGCGCCGC-- TGCTGCTGGG CTCCGCGCGT 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  GACCACCTGG GTGAGGACGT GCTTCTGT-- TCACCACGGA CGGGGTCAAT 
gi_229652641_gb  GACCACCTGG GTGAGGACGT GCTTCTGT-- TCACCACGGA CGGGGTCAAT 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  GTACCGAACA ACGCTCCCTG AAAACTGC-- AGCCACCCTA CACCCCTCTC 
gi_88626309_gb_  GTACCGAACA ACGCTCCCTG AAAACTGC-- AGCCACCCTA CACCCCTCTC 
gi_88654284_gb_  GTACCGAACA ACGCTCCCTG AAAACTGC-- AGCCACCCTA CACCCCTCTC 
gi_114718999_gb  GTACCGAACA ACGCTCCCTG AAAACTGC-- AGCCACCCTA CACCCCTCTC 
gi_114718270_gb  GTACCGAACA ACGCTCCCTG AAAACTGC-- AGCCACCCTA CACCCCTCTC 
gi_114744710_gb  AGGCACCCCC ACCCCCACAT CGCATCGT-- ACCCAGGACA GAATTCGGAA 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  CCACAATAAA GCCCGTGCAC ACAGTCCC-- CCTACCTACG CACTCCCGAC 
gi_114474748_gb  CCACAATAAA GCCCGTGCAC ACAGTCCC-- CCTACCTACG CACTCCCGAC 
gi_114450604_gb  GGTGTGTCAG GCACCACCGG GCGCCAGGGA AACCTAGGTA AGCACACGCC 
 
gi_31084151_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88627441_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88629151_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88620401_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88644845_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_114492173_gb  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88634142_gb_  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_280968126_gb  GGTTTGCACA ATGCCACCCA GAGAACATTC CAGATCGACT ACCGCCGTAA 
gi_88640218_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  GAGGAGTTCC -TGCAGTGCG GGGCGCTCCA GGGGCTCTAC GCCACCGTGG 
gi_229652641_gb  GAGGAGTTCC -TGCAGTGCG GGGCGCTCCA GGGGCTCTAC GCCACCGTGG 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  ---------- ---GGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  TTCTCCATCC AGTGGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_88626309_gb_  TTCTCCATCC AGTGGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_88654284_gb_  TTCTCCATCC AGTGGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_114718999_gb  TTCTCCATCC AGTGGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_114718270_gb  TTCTCCATCC AGTGGCGTCC ATGACCGGGC CTACGTCTCT GTGAACGGGG 
gi_114744710_gb  ACTTGGTGAC TGCCGCAGCG TCATCCAGTC C--TGACCTG CGCGGCACCG 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  CTTTTATGTG GGTAACTTCA CTATTC---- ---CCAGCGG GATCTCAGAC 
gi_114474748_gb  CTTTTATGTG GGTAACTTCA CTATTC---- ---CCAGCGG GATCTCAGAC 
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gi_31084151_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88627441_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88629151_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88620401_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88644845_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_114492173_gb  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88634142_gb_  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_280968126_gb  CCGCTTCCTC AAGGATGGCC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_88640218_gb_  ---------- --------CC AGCCCTTCCG CTA-CATCTC GGGAAGCATT 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ACTTCAGCAC AGGTTCCAAC CTCACAGCTG CTTTCATGCT CCAGAGGAAA 
gi_229652641_gb  ACTTCAGCAC AGGTTCCAAC CTCACAGCTG CTTTCATGCT CCAGAGGAAA 
gi_88636859_gb_  -------GGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_88629496_gb_  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_114496738_gb  ---------- ---CCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_88615585_gb_  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_88626309_gb_  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_88654284_gb_  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_114718999_gb  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_114718270_gb  TTGCCCAGGG AGTCCTTGAA CGAGAATCTG TGATCACCCT GAACATAACA 
gi_114744710_gb  AAGCCACAGG AGGGACCGAA CACGTCTCCT G--TGAAGCA GGGGTCAGGT 
gi_88634842_gb_  ---------- ----CTTCCT CCAGTTTCCT GGATGGACCA AGGGTCAGGT 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  TTGCCTCAGG ACACCTTCCT CCAGTTTCCT GGATGGACCA AGGGTCAGGT 
gi_114474748_gb  TTGCCTCAGG ACACCTTCCT CCAGTTTCCT GGATGGACCA AGGGTCAGGT 
gi_114450604_gb  AGGTATGTGC AAGGCTGGAA CTCTGAAGGG TCACAGTCTT TGTCCCAGGG 
 
gi_31084151_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88627441_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88629151_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88620401_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88644845_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_114492173_gb  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88634142_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_280968126_gb  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_88640218_gb_  CACTATTTCC GCGTGCCTCG CTTCTACTGG -AAGGACCGG CTGCTGAAGA 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  TTTGAGCCCA GAGGACCCCT GATCAATTCT -GAATTCTA- -CACTGGATG 
gi_229652641_gb  TTTGAGCCCA GAGGACCCCT GATCAATTCT -GAATTCTA- -CACTGGATG 
gi_88636859_gb_  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_88629496_gb_  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_114496738_gb  GGGGA--AGC TGTAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_88615585_gb_  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_88626309_gb_  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_88654284_gb_  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_114718999_gb  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_114718270_gb  GGGGA--AGC TGGAGCGACC TTGGACCTCC -TGGTGGAGA ATATGGGGCG 
gi_114744710_gb  GTGGATCAAC GGCTTTAACC TCGG--CCGC -TACTGGCCA GTGCAGGGCC 
gi_88634842_gb_  GTGGATCAAC GGCTTTAACC TCGG--CCGC -TACTGGCCA GTGCAGGGCC 
gi_114747744_gb  ---------- --CTTTAACC TCGG--CCGC -TACTGGCCA GTGCAGGGCC 
gi_114475416_gb  GTGGATCAAC GGCTTTAACC TCGG--CCGC -TACTGGCCA GTGCAGGGCC 
gi_114474748_gb  GTGGATCAAC GGCTTTAACC TCGG--CCGC -TACTGGCCA GTGCAGGGCC 
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gi_31084151_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88627441_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88629151_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88620401_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88644845_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_114492173_gb  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88634142_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_280968126_gb  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_88640218_gb_  TGAAGATGGC TGGGCTGA-A CGCCATCCA- GACGTACGTG GCCTGGAACT 
gi_229650957_gb  ---GGATCAT TGGGGCCA-A CGTCATTCA- ACAGT---CA GCTCTAAAGC 
gi_280977021_gb  GTTAGATCAT TGGGGCCA-A CGTCATTCA- ACAGT---CA GCTCTAAAGT 
gi_229652641_gb  GTTAGATCAT TGGGGCCA-A CGTCATTCA- ACAGT---CA GCTCTAAAGT 
gi_88636859_gb_  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_88629496_gb_  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_114496738_gb  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_88615585_gb_  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_88626309_gb_  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_88654284_gb_  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_114718999_gb  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_114718270_gb  TGTGAACTAT G--GCTCATA TATCAACG-- ATTTCAAGGG TCTTGTTTCT 
gi_114744710_gb  CCCAGATGAC CCTGTTCGTG CCTCAGCAC- ATCCTGGTGA CTTCGACCCC 
gi_88634842_gb_  CCCAGATGAC CCTGTTCGTG CCTCAGCAC- ATCCTGGTGA CTTCGACCCC 
gi_114747744_gb  CCCAGATGAC CCTGTTCGTG CCTCAGCAC- ATCCTGGTGA CTTCGACCCC 
gi_114475416_gb  CCCAGATGAC CCTGTTCGTG CCTCAGCAC- ATCCTGGTGA CTTCGACCCC 
gi_114474748_gb  CCCAGATGAC CCTGTTCGTG CCTCAGCAC- ATCCTGGTGA CTTCGACCCC 
gi_114450604_gb  TGCGAAAAAC CG-GCTTGTC CACGAACTCC ACGGTGCATA GTTCCGGGTC 
 
gi_31084151_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCTGGGGA CCATGATGTG 
gi_88627441_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_88629151_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_88620401_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_88644845_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_114492173_gb  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_88634142_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_280968126_gb  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_88640218_gb_  TCCATGAGCT GCAGCCTGGA CGGTACAATT TCTCCGGGGA CCATGATGTG 
gi_229650957_gb  G--GCGGCTT TCACCCTTCA TGATATGCTT GCTCTTGGGG CAAATGTAAA 
gi_280977021_gb  G--GTGGCTT TCACCCTTCA TGATATGCTT GCTCTTGGGG CAAATGTAAA 
gi_229652641_gb  G--GTGGCTT TCACCCTTCA TGATATGCTT GCTCTTGGGG CAAATGTAAA 
gi_88636859_gb_  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_88629496_gb_  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_114496738_gb  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGACA TCTTCCCGCT 
gi_88615585_gb_  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_88626309_gb_  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_88654284_gb_  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_114718999_gb  AACCTGACCC TTGATTCCAA ATCCTCACCC AACTGGGAGA TCTTCCCGCT 
gi_114718270_gb  AACCTGACCC TTGATTCCAA AATCCTCACC AACTGGGAGA TCTTCCCGCT 
gi_114744710_gb  AAACATCATC GTGGTGCTGG AG-CTGGAGT ATGCGCCCTG CCAGGACGGT 
gi_88634842_gb_  AAACATCATC GTGGTGCTGG AG-CTGGAGT ATGCGCCCTG CCAGGACGGT 
gi_114747744_gb  AAACATCATC GTGGTGCTGG AG-CTGGAGT ATGCGCCCTG CCAGGACGGT 
gi_114475416_gb  AAACATCATC GTGGTGCTGG AG-CTGGAGT ATGCGCCCTG CCAGGACGGT 
gi_114474748_gb  AAACATCATC GTGGTGCTGG AG-CTGGAGT ATGCGCCCTG CCAGGACGGT 
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gi_31084151_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88627441_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88629151_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88620401_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88644845_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_114492173_gb  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88634142_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_280968126_gb  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_88640218_gb_  GAACATTTCA TTCAGCTGGC ACATGAGCTG GGACTGCTGG TC-ATCCTGA 
gi_229650957_gb  CATGTACATG TTTATAGGTG GCAGCAATTT TGCCTATTGG A--ATGGAGC 
gi_280977021_gb  CATGTACATG TTTATAGGTG GCAGCAATTT TGCCTATTGG A--ATGGAGC 
gi_229652641_gb  CATGTACATG TTTATAGGTG GCAGCAATTT TGCCTATTGG A--ATGGAGC 
gi_88636859_gb_  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGACCGGG GG--TGGCAG 
gi_88629496_gb_  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGACCGGG GG--TGGCAG 
gi_114496738_gb  GGACATGGAG AA-------- ---------- ---------- ---------- 
gi_88615585_gb_  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGACCGGG GG--TGGCAG 
gi_88626309_gb_  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGACCGGG GG--TGGCAG 
gi_88654284_gb_  GGACATGGAG AATGCAGTAC TCAGTCACCT GNGGACCGGG GG--TGGCAG 
gi_114718999_gb  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGGACGGG GGGGTGGCAG 
gi_114718270_gb  GGACATGGAG AATGCAGTAC TCAGTCACCT GGGGACCGGG GG--TGGCAG 
gi_114744710_gb  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_88634842_gb_  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_114747744_gb  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_114475416_gb  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_114474748_gb  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_114450604_gb  TGGGGTCGAA GTCACCAGGA TGTGCTGAGG CACGAACAGA GTCATCTGGG 
 
gi_31084151_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACC--- 
gi_88627441_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_88629151_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_88620401_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_88644845_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_114492173_gb  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_88634142_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_280968126_gb  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_88640218_gb_  GGCCTGGACC CTACATCTGT GCAGAGTGGG ACATGGG-AG GATTACCTGC 
gi_229650957_gb  AAACACGCCC TACCAACCAC AGCCCACCAG CTACGACTAT GATGCCCCGC 
gi_280977021_gb  AAACACGCCC TACCAACCAC AGCCCACCAG CTACGACTAT GATGCCCCGC 
gi_229652641_gb  AAACACGCCC TACCAACCAC AGCCCACCAG CTACGACTAT GATGCCCCGC 
gi_88636859_gb_  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_88629496_gb_  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_88626309_gb_  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_88654284_gb_  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_114718999_gb  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CC-TACCTAC 
gi_114718270_gb  TGACAGGCGC TA-CCACAAT AAAGCCCGTG CACACAGTCC CCCTACCTAC 
gi_114744710_gb  AGTCTAGACC CA-CAGACAT GCAAACTAGG AGCA-AGACT CATGGCCGAC 
gi_88634842_gb_  AGTCTACACC CC-CAGACAT GCAAACTAGG ---------- ---------- 
gi_114747744_gb  AGTCTAGACC CA-CAGACAT GCAAACTAGG AGCA-AGACT CATGGCCGAC 
gi_114475416_gb  AGTCTAGACC CA-CAGACAT GCAAACTAGG AGCA-AGACT CATGGCCGAC 
gi_114474748_gb  AGTCTAGACC CA-CAGACAT GCAAACTAGG AGCA-AGACT CATGGCCGAC 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_88629151_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_88620401_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_88644845_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_114492173_gb  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_88634142_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_280968126_gb  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_88640218_gb_  TTGGCTGTTG GAGAAAAAAT CTATTGTTCT CCGTTCTTCA GATCCAGATT 
gi_229650957_gb  TGAGCGAGGC TGGGGACCTC ACGGAGAAGT ATTTTGCTCT GCGGGATATT 
gi_280977021_gb  TGAGCGAGGC TGGGGACCTC ACGGAGAAGT ATTTTGCTCT GCGGGATATT 
gi_229652641_gb  TGAGCGAGG- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  GCACTCCCGA CCTTTTATGT GGGTAACTTC ACTATTCCC- AGCGGGATCT 
gi_88629496_gb_  GCACTCCCGA CCTTTTATGT GGGTAACTTC ACTATTCCC- AGCGGGATCT 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  GCACTCCCGA CCTTTTATGT GGGTAACTTC ACTATTCCC- AGCGGGATCT 
gi_88626309_gb_  GCACTCCCGA CCTTTTATGT GGGTAACTTC ACTATTCCC- AGCGGGATCT 
gi_88654284_gb_  GCACTCCCGA CCTTTTATGT GG-------- ---------- ---------- 
gi_114718999_gb  GCACTCCCGA CTTTTTATGT GGGTAACTTC ACTATTCCCC AGCGGGATCT 
gi_114718270_gb  GCACTCCCGA CCTTTTATGT GGGTAACTTC ACTATTCCC- AGCGGGATCT 
gi_114744710_gb  TC-CCTGGGA CAAAGACTGT GACCCTT--- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  TC-CCTGGGA CAAAGACTGT GACCCTTCAG AGTTCCAGCC TTGCACATAC 
gi_114475416_gb  TC-CCTGGGA CAAAGACTGT GACCCTTCAG AGTTCCAGCC TTGCACATAC 
gi_114474748_gb  TC-CCTGGGA CAAAGACTGT GACCCTTCAG AGTTCCAGCC TTGCACATAC 
gi_114450604_gb  TGACCCTTGG TCCATCCAGG AAACTGGAGG AAGGTGTCCT GAGGCAAGTC 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_88629151_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_88620401_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_88644845_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_114492173_gb  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_88634142_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_280968126_gb  ATCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_88640218_gb_  ACCTTGCGGC TGTGGACAAG TGGCTGGGGG TCCTTCTGCC CAAGATGAGG 
gi_229650957_gb  ATTCAGAAGT T-TGCAAAAG TACCGGAAGG TCCTATCCCC CCATCCACAC 
gi_280977021_gb  ATTCAGAAGT T-TGCAAAAG TACCGGAAGG TCCTATCCCC CCATCCACAC 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  CAGACTTGCC TCAGGACACC TTCCTCCAGT TTCCTGGATG GACCAAGGGT 
gi_88629496_gb_  CAGACTTGCC TCAGGACACC TTCCTCCAGT TTCCTGGATG GACCAAGGGT 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  CAGACTTGCC TCAGGACACC TTCCTCCAGT TTCCTGGATG GACCAAGGGT 
gi_88626309_gb_  CAGACTTGCC TCAGGACACC TTCCTCCAGT TTCCTGGATG GACCAAGGGT 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  CAGACTTGCC TCAGGACACC TTCCTCCGGT TTCCTGGAT- ---------- 
gi_114718270_gb  CAGACTTGCC TCAGGACACC TTCCTCCAGT TTCCTGGATG GACCAGGG-- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  CTCATCTGCC ACTCGGAAGG CCAGCATTCA CTTCTGATTG GAAGATGGGC 
gi_114475416_gb  CTCATCTGCC ACTCGGAAGG CCAGCATTCA CTTCTGATTG GAAGATGGGC 
gi_114474748_gb  CTCATCTGCC ACTCGGAAGG CCAGCATTCA CTTCTGATTG GAAGATGGGC 
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gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_88629151_gb_  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_88620401_gb_  CCC--CTCCT CTA------- ---------- ---------- ---------- 
gi_88644845_gb_  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_114492173_gb  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_88634142_gb_  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_280968126_gb  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_88640218_gb_  CCC--CTCCT CTATAAGAAC GGAGGCCCGA TTATAACAGT GCAGGTTGAA 
gi_229650957_gb  CAAAGTTTGC ATATGGAAAA GTTGCTCTGA AAAAGTTAAA GACGGTGGAG 
gi_280977021_gb  CAAAGTTTGC ATATGGAAAA GTTGCTCTGA AAA-GTTAAA GACGGTGGAG 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  CAGGTGTGGA TCAACGGCTT TAACCTCGGC CGCTACTGGC CAGTGCAGGG 
gi_88629496_gb_  CAGGTGTGGA TCAACGGCTT TAACCTCGGC CGCTACTGGC CAGTGCAGGG 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  CAGGTGTGGA TCAACGGCTT TAACCTCGGC CGCTACTGGC CAGTGCAGGG 
gi_88626309_gb_  CAGGTGTGGA TCAACGGCTT TAACCTCGGC CGCTACTGGC CAGTGCAGGG 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  TCAGTGTGGA TCAACGGCTT TAC------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  TAGGTGTGTG CTTACCTAGG TTTCCCTGGC GCCCGGCGGT GCCTGACACA 
gi_114475416_gb  TAGGCGTGTG CTTACCTAGG TTTCCCTGGC GCCCGGCGGT GCCTGACACA 
gi_114474748_gb  TAGGCGTGTG CTTACCTAGG TTTCCCTGGC GCCCGGCGGT GCCTGACACA 
gi_114450604_gb  CGTAGGTAGG GGGACTGTGT GCACGGGCTT TATTGTGGTA GCGCCTGTCA 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_88629151_gb_  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_114492173_gb  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_88634142_gb_  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_280968126_gb  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_88640218_gb_  AATGAATATG GCAGCTACTA TTCCTGTGAT TACGACTACT TGCGTTTCCT 
gi_229650957_gb  GATGCTCTCA ACATCCTGTG TCCCTCTGGA CCCATAAAAA GTGTTTATCC 
gi_280977021_gb  GATGCTCTNC ACATCCTGTG TCCCTCTGGA CCCATAAAAA GTGTTTATCC 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  CCCCCAGATG ACCCTGTTCG TGCCTCAGCA CATCCTGGTG ACTTCGACCC 
gi_88629496_gb_  CCCCCAGATG ACCCTGTTCG TGCCTCAGCA CATCCTGGTG ACTTCGACCC 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  CCCCC----- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  CCCCCAGATG ACCCTGTTCG TGCCTCAGCA CATCCTGGTG ACTTCGACCC 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  CCCCGTCCAG GCTGCGTGGT CATGGGGCGG GGCTGGTAGC CCAGCAACAC 
gi_114475416_gb  CCCCGTCCAG GCTGCGTGGT CATGGGGCGG GGCTGGTAGC CCAGCAACAC 
gi_114474748_gb  CCCCGTCCAG GCTGCGTGGT CATGGGGCGG GGCTGGTAGC CCAGCAACAC 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  GCAGAAGCGT TTCCAGGACC ACCTGGGTGA GGACGT---- ---------- 
gi_88629151_gb_  GCAGAAGCGT TTCCAGGACC ACCTGGGTGA GGACGTGCTT CTGNTCACCA 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  GCAGAAGCGT TTCCAGGAC- ---------- ---------- ---------- 
gi_114492173_gb  GCAGAAGCGT T--------- ---------- ---------- ---------- 
gi_88634142_gb_  GCAGAAGCGT TTCCAGGACC ACCTGGGTGA GGACGTGCTT CTGTTCACCA 
gi_280968126_gb  GCAGAAGCGT TTCCAGGACC ACCTGGGTGA GGACGTGCTT CTGTTCACCA 
gi_88640218_gb_  GCAGAAGCGT TTCCAGGACC ACCTGGGTGA GGACGTGCTT CTGTTCACCA 
gi_229650957_gb  CTTGACGTTT GTTGATGTGA AACAGTACTT TGGATTTGTG C--------- 
gi_280977021_gb  CTTGACGTTT GGTGATGTGA AACAGTACTT TGGATTTGTG CTGTACCGAA 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  CAAACATCAT CGTGGTGCTG GAGCTGGAGT ATGCGCCCTG CCACGACGGT 
gi_88629496_gb_  CAAACATCAT CGTGGTGCTG GAGCTGGAGT ATGCGCCCTG CCAGGACGGT 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  CCAACATCAT CGTGGTGCTG ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  AGAGGCATCC ACAGGGTTGG AAGGGAAGCA TTTGAAGTTT TTCTGATTTT 
gi_114475416_gb  AGAGGCATCC ACAGGGTTGG AAGGGAAGCA TTTGAAGTTT TTCTGATTTT 
gi_114474748_gb  AGAGGCATCC ACAGGGTTGG AAGGGAAGCA TTTGAAGTTT TTCTGATTTT 
gi_114450604_gb  GGAAGATCTC CCAGTTGGTG AGGATTTTGG AATCAAGCTC GTGCCG---- 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  CGGACGGGGT CAATG----- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  CGGACGGGGG TCATGAGGAG TTCCTGCAGT GCGGGG---- ---------- 
gi_280968126_gb  CGGACGGGGT CAATGAGGAG TTCCTGCAGT GCGGGGCGCT CCAGGGGCTC 
gi_88640218_gb_  CGGACGGGGT CAATGAGGAG TTCCTGCAGT GCGGGGCGCT CCAGGGGCTC 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  CAACGCTCCC TGAAA----- ---------- ---------- ---------- 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  GACCCGGAAC TATGCACCGT GG-------- ---------- ---------- 
gi_88629496_gb_  GACCCGGAAC TATGCACCGT GGAGTTCGTG GACAAGCCGG TTTTTCGCAC 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  TATTTTGTTA AGAATCATGT AGCCTTTTTA TTAAATAAAA TTTGTATTCA 
gi_114475416_gb  TATTTTGTTA AGAATCATGT AGCCTTTTTA TTAAATAAAA TTTGTATTCA 
gi_114474748_gb  TATTTTGTTA AGAATCATGT AGCCTTTNTA TTAAATAAAA TTTGTATTCA 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  TACGCCACCG TGGACTTCAG CACAGGTTCC AACCTCACAG CTGCTTTCAT 
gi_88640218_gb_  TACGCCACCG TGGACTTCAG CACAGGTTCC AACCTCACAG CTGCTTTCAT 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ---------- ---------- ---------- ---------- ---------- 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  AGTCTAGACC CACAGACATG CAAACTAGGA GCAAGACTCA TGGCCGACTC 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  AATG------ ---------- ---------- ---------- ---------- 
gi_114475416_gb  AAT------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  AAT------- ---------- ---------- ---------- ---------- 
gi_114450604_gb  ---------- ---------- ---------- ---------- ---------- 
 
gi_31084151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88627441_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629151_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88620401_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88644845_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114492173_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634142_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_280968126_gb  GCTCCAGAGG AAATTTGAGC CCAGAGGACC CCTGATCAAT TCTGAATTCT 
gi_88640218_gb_  GCTCCAGAGG AAATTTGAGC CCAGAGGACC CCTGATCAAT TCTGAATTCT 
gi_229650957_gb  ---------- ---------- ---------- ---------- ---------- 
gi_280977021_gb  ---------- ---------- ---------- ---------- ---------- 
gi_229652641_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88636859_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88629496_gb_  CCTGGGACAA AGACTGTGAC CCTTCAGAGT TCCAGCCTTG CACATAC--- 
gi_114496738_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88615585_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88626309_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_88654284_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114718999_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114718270_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114744710_gb  ---------- ---------- ---------- ---------- ---------- 
gi_88634842_gb_  ---------- ---------- ---------- ---------- ---------- 
gi_114747744_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114475416_gb  ---------- ---------- ---------- ---------- ---------- 
gi_114474748_gb  ---------- ---------- ---------- ---------- ---------- 




Appendix Figure 2 (cont.) 
 
gi_31084151_gb_  ---------- ---------- ---------- ------- 
gi_88627441_gb_  ---------- ---------- ---------- ------- 
gi_88629151_gb_  ---------- ---------- ---------- ------- 
gi_88620401_gb_  ---------- ---------- ---------- ------- 
gi_88644845_gb_  ---------- ---------- ---------- ------- 
gi_114492173_gb  ---------- ---------- ---------- ------- 
gi_88634142_gb_  ---------- ---------- ---------- ------- 
gi_280968126_gb  ACACTGGATG GTTA------ ---------- ------- 
gi_88640218_gb_  ACACTGGATG GTTAGATCAT TGGGGGCAAC GTCATTC 
gi_229650957_gb  ---------- ---------- ---------- ------- 
gi_280977021_gb  ---------- ---------- ---------- ------- 
gi_229652641_gb  ---------- ---------- ---------- ------- 
gi_88636859_gb_  ---------- ---------- ---------- ------- 
gi_88629496_gb_  ---------- ---------- ---------- ------- 
gi_114496738_gb  ---------- ---------- ---------- ------- 
gi_88615585_gb_  ---------- ---------- ---------- ------- 
gi_88626309_gb_  ---------- ---------- ---------- ------- 
gi_88654284_gb_  ---------- ---------- ---------- ------- 
gi_114718999_gb  ---------- ---------- ---------- ------- 
gi_114718270_gb  ---------- ---------- ---------- ------- 
gi_114744710_gb  ---------- ---------- ---------- ------- 
gi_88634842_gb_  ---------- ---------- ---------- ------- 
gi_114747744_gb  ---------- ---------- ---------- ------- 
gi_114475416_gb  ---------- ---------- ---------- ------- 
gi_114474748_gb  ---------- ---------- ---------- ------- 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Figure 4 (cont.) 
CTGGCGGTAAAACTCTCCCTATGGGAAATGAGTTCCTGCAGAGACTGGGAGCTCTGTCACTGCCGTCCTGGCATCGA
GCGCTTTTAGTAGGCCTTTCATGTATATTTTAGGCTCTGAAAATATTTCTCTCTCCAAGTTTGATTGAAAATGGAGT
TTGTGGGGGTTTTTCATTCTTCTTGCTGATATTTTATAATTTCCCAGAGAAGATGAAAATGCAGATTTTTGCAACTC
TGTTCATACCAAAAGTCATAATGAAGTCATTTTTGACCCAAAGACCACCCACTAATTTCTGGAACTAGGAGGCAAGT
CAATCAATCTTTGAACTCTGTCACACAAAGTTTTATTAGAAACATATTGGGGATTTTGGAGAGAGGACTGGTGAACT
TTGTGTAGTGAAATAGAAACTTGAGTTGCCAGCATAGACTACTTAATTAAGAGATAAGGAAATTCACTCATTCACTA
AAAAATAATTGAACAACTGCTCTGTGCTAGGCATTTTACTAAGCAGTTAGGTGATGATTATTGTTGCTGGAGCTGGT
TTACTTCATTATTAAAATGTTGTTTCCCCTGAACTCAATTGCTTGGGGATAAAAAAACACCAACCTTATCTATGTAA
AGAGAAGGCTGAAATGAGTTTCAAAACTAGTTAGTGGAGTTCTGATATTCTGAAAGGGGAATTTGAAGCCATTAGAA
GCTTTTGAGGAGTAAAGTATTTTTTAAAAAACTTTATTGAAATGTAGTTGATTTGAAATGTTGTCTTAGTTTCAGCT
GTACAGCAAAATGATTCAGTTATACATATATATCTATTCTTTTTCTGATTCTTTTCCATTACAGGCTATTAGGTTAT
TACAGGATATTGAAGATTGTTGCTTGTGCTATAGGTCCTTGCTGGTTATTCCATGTGTAGTAGTGTGTGTATTTTGA
CCCCAAACTCCTAATTTATCCCTCCCCCTTTGCTTCTCCCTTTTTAACCATAAGTTTGGTTTTTACATCTGTGAGTC
TATTCCTGTTTTGTAAATACATTCATTTGTATCATTTTTTTTAGATTCCACATGTAAGTAACATCATAGGATATTTG
TCTTTCTCCGTCTGATCTACTTAGTAAAATAATCTCTGGTTCCATCCATGTTGCTGCCAATGGCATTAGTTGATTCT
TTTTACAGCTAATATTCTATTGTGTATGTATATATATACGACATCGTCATGCATTCATCTGCAGCACTTAAGCTGCT
TCCATGTCTTAGCTATTGTGAATAGTGCTGCTATGAACACTGGGCTGCATGTGTCTTTTCGAGTGGGAGTTTTCTCC
AGGTGTATGCCCAGGATTGGGATTGCTAGATTATGGCAGCTCCATTATTCATTTTTTAAGGAACCTCCATACAGTTT
TTCATAGTGGCTGCACCAATTTAGATTACCACCAACTGTGTAGGATGGTTCCCTTTTCTCCACACGCTCTCTAGCGT
TATTTTCTCCCCATTTTTGGTGATGGTGGTGGTGGTCATACCACTTGGCTTGTGGGATCTTAGTTCCCCGACCAGGG
ATGGAACCCAGGCCTTGGCATTGAAAGCAGTGAAAGTGAAAGTCCTAACCACTGGACCATTAGGGAACTCCCTCCAG
CATTTACTGTTTACAGACTTTTTGATAATGGCCATTCAGGAGTGAAGTATCATGACCCCAGAAATGAATGGAACTTG
TGTCTGGTTCATCTGAGTCCAGGAAGCCACAGACCAGTGCAGAGTACAGGACCTCATGGCCAAGGGTAGAGCTGAGC
TGTTACCATAACAGAATAGGGATGATGGCTCAGGGTTTGAGGCAGGTGAATTATGACAGCAAAGGCGAGGCTGACTG
AAGGAAGCACATGAACCAAGAGTCAAATGGGGTTGCTAGCCAGAGGGTGATGAATGGACAGCCTGATGCAGACTCTG
TGCATCCTCATTTTCCCACACCTGGGGTCAAGCCTATTTATATTAGGTGATGATCCAGAACTCCCATTTTAGACTTG
AGTTCCTGGGAGCAGACCCTGAGACTGAGATGAGCATACAGGAGATTCACTGGGGAGTCCTCTTGGGAACAACATCT
GTAAGGGCATGAAGGAAGCAGGACTGGGCAACAGAGGCTGATCTTATGGGCAGCTCTGCGGCTGGAATGGCTTGTCA
GCATGTCCCAAATTAAAGCAAGGGAGCAAGTGTTTCTTTCCCCTCAAGACTCAGGCACTGGAAGTGAGCTGCCCCCC
TGTGAGGACAGTCCTGAAGAGACCAGCCGAGAGCCCCAGGTGTCAGCGCTCCTGGAGCCGATGGGGTGAGTACTCCT
CATTCTGCACAGGGTGTGTGGACAGCATCCCACAACCCCAACAGTCTCCTCCAGCCTGATGCAGGAGGGCCGCTGTC
CCAGGAGCTCAAAACCACGGCCAAAAATGAGGTCCCTAAGTTTTCCTTTGTCTCAGCTTTTCCTCTTTTGCCCCTCT
CCCCACCCAACCCCCCCTTCACTTTAACTACAAAAACCCACGCACCCCTCCCTGACCACAAGGGGCAGTCTTGACAC
AGCATCTGCCTTTTCACGTGCAATTTCACCAGCTTAGAATGTCCTTCCTCCCTTCCATTCACCAAAATCAGGCTCCT
CTTACAAGGCCAACTTCAAAAGCTAGTTGAAGTTTGACATTTGACATTGGTTCCTTCTTTGTCTGGGGTCCTGAGGC
ATTTTGTTTGTGACTCGGTTATTGCATCTGTCCTGCTTGCTTCTTAGTTGACCTTGTTCTTGTGTCTTCCCTTCTCA
GGTTACAATCTATACATGCAGCGCTCACTCCTTTATCCTACCTCCTCTCCACTACCCACCATCCCGCGTGGTACAAG
ACAGACTCCCAGCAAATCAGAAATCATTGCATAAAATGTCCCAGAGTGTTATTACAGTTTCTTGTGAAAAATCTCCA
TAAAGGTCTATACATCAACCAGCATTCTTCCTTCTCTTGGGAGAATTCTTCC 
 
 
